Is the Time of Appearance and Resolution of De Novo HLA-DP Donor Specific Antibodies Associated with Reduced Deleterious Effect on Lung Transplant Outcomes?

A. Zhang,¹ Y. Sun,² K. McCurry,³ M. Budev.³

¹Allogen Laboratories, Cleveland Clinic, Cleveland, OH
²Avalon University School of Medicine, Willemstad, Netherlands Antilles
³Transplantation Center, Cleveland Clinic, Cleveland, OH

Meeting: 2017 American Transplant Congress

Abstract number: B252

Keywords: Graft survival, HLA antibodies, Obilterative bronchiolitis

Session Information

Session Name: Poster Session B: Lung Transplantation Poster Session

Session Type: Poster Session

Date: Sunday, April 30, 2017

Session Time: 6:00pm-7:00pm

Presentation Time: 6:00pm-7:00pm

Location: Hall D1

Introduction: The impact of HLA-DP de novo donor specific antibodies (dDSA) to lung transplantation (LT) is poorly understood. This study analyzed the association of timely appearance of DP dDSA to LT outcomes.

Methods: We retrospectively analyzed 720 recipients who underwent lung Tx at Cleveland Clinic from 2008 to 2015. dDSA were identified using Luminex single antigen assay. Median post operation days (POD) and median resolution days were used to record the time of dDSA appearing and disappearing, respectively. DP dDSA only and DP + other HLA dDSA were compared for two-year graft survival, antibody mediated rejection (AMR), acute cellular rejection (ACR), and bronchiolitis obliterans syndrome (BOS).

Results: In the study cohort, 8% (58/720) developed de novo DP antibody, of which 31% (18/58) had DP dDSA and 41% (24/58) had other HLA dDSA. Comparing the production and resolution time between DP dDSA and the other HLA dDSA, DP dDSA took significantly longer time than other dDSA to develop, but needed remarkably shorter time to resolve (Table 1a). DP dDSA alone presented fewer incidence of AMR and higher rate of two-year graft survival than DP dDSA combined with other dDSA. However, ACR and BOS were equivalent (Table 2b).

Conclusion: Without the involvement of other HLA dDSA, DP dDSA alone cause little deleterious effect on LT, which might be due to its slow development and quick resolution. This finding warrants further investigation of larger cohort studies.

CITATION INFORMATION: Zhang A, Sun Y, McCurry K, Budev M. Is the Time of Appearance and Resolution of De Novo HLA-DP Donor Specific Antibodies Associated with Reduced Deleterious Effect on Lung Transplant Outcomes? Am J Transplant. 2017;17 (suppl 3).

To cite this abstract in AMA style:

Zhang A, Sun Y, McCurry K, Budev M. Is the Time of Appearance and Resolution of De Novo HLA-DP Donor Specific Antibodies Associated with Reduced Deleterious Effect on Lung Transplant Outcomes? [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/is-the-time-of-appearance-and-resolution-of-de-novo-hla-dp-donor-specific-antibodies-associated-with-reduced-deleterious-effect-on-lung-transplant-outcomes/. Accessed May 29, 2025.

« Back to 2017 American Transplant Congress